3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Hepatocellular
121
Carcinoma, Renal Cell
60
Neoplasms
43
Liver Neoplasms
42
Neoplasm Metastasis
23
Carcinoma, Non-Small-Cell Lung
21
Leukemia, Myeloid, Acute
20
Melanoma
18
Kidney Neoplasms
16
Breast Neoplasms
16
Brain Neoplasms
13
Pancreatic Neoplasms
12
Sarcoma
11
Prostatic Neoplasms
10
Glioblastoma
10
Lung Neoplasms
9
Thyroid Neoplasms
8
Recurrence
8
Rectal Neoplasms
8
Colorectal Neoplasms
8
Precursor Cell Lymphoblastic Leukemia-Lymphoma
7
Colonic Neoplasms
7
Stomach Neoplasms
6
Ovarian Neoplasms
6
Multiple Myeloma
6
Leukemia
6
Gliosarcoma
6
Carcinoma
6
Unspecified Adult Solid Tumor, Protocol Specific
5
Urinary Bladder Neoplasms
4
Interventions
pertuzumab
1
pazopanib
1
daratumumab
1
Trastuzumab
1
Surgical Procedures, Operative
1
Sunitinib
1
Sorafenib
1
Risk Assessment
1
Radiotherapy
1
Injections, Subcutaneous
1
Focus Groups
1
Bandages, Hydrocolloid
1
Ado-Trastuzumab Emtansine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Patient Preference
×
Sorafenib
×
Clear all
NCT02616692
2017-09-27
HCC Patient Preferences in Japan
Bayer
Completed
120 enrolled